EUCAST technical note on anidulafungin

Clinical Microbiology and Infection

Volumn 17, Issue 11, 2011, Pages

  Arendrup, M C ^a   Rodriguez Tudela, J L ^b   Lass Florl C ^c   Cuenca Estrella, M ^b   Donnelly, J P ^d   Hope, W ^e  

^a STATENS SERUM INSTITUT   (Denmark)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Anidulafungin; Breakpoints; EUCAST Technical Note; Susceptibility testing

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; MICAFUNGIN;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 80054077681     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03647.x     Document Type: Article

References (15)

1. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. Breakthrough invasive candidiasis on micafungin. J Clin Microbiol 2010; 48: 2373-2380.
2. Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D et al. Infections due to Candida spp. with reduced susceptibility to caspofungin in France. European Conference on Clinical Microbiology and Infectious Diseases. Abstract O346. Clin Microbiol Infect 2010; 16 (Suppl 2): S77.
3. Arendrup MC, Garcia-Effron G, Buzina W et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother 2009; 53: 1185-1193.
4. Arendrup MC, Garcia-Effron G, Lass-Florl C et al. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother 2010; 54: 426-439.
5. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-2482.
6. Vazquez JA, Schranz JA, Clark K, Goldstein BP, Reboli A, Fichtenbaum C. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr 2008; 48: 304-309.
7. Krause DS, Simjee AE, van RC et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39: 770-775.
8. Damle BD, Dowell JA, Walsky RL, Weber GL, Stogniew M, Inskeep PB. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob Agents Chemother 2009; 53: 1149-1156.
9. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004; 44: 590-598.
10. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57: 705-708.
11. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 2009; 53: 112-122.
12. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1, 3-{beta}-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother 2009; 53: 3690-3699.
13. Desnos-Ollivier M, Bretagne S, Raoux D, Hoinard D, Dromer F, Dannaoui E. Mutations in the fks1 gene in Candida albicans, C. tropicalis and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the EUCAST method. Antimicrob Agents Chemother 2008; 52: 3092-3098.
14. Baixench MT, Aoun N, Desnos-Ollivier M et al. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 2007; 59: 1076-1083.
15. Pfaller MA, Diekema DJ, Andes D et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14: 164-176.